Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.
Using murine models, we have previously demonstrated that recombinant adeno-associated virus (rAAV)-mediated microdystrophin gene transfer is a promising approach to treatment of Duchenne muscular dystrophy (DMD). To examine further therapeutic effects and the safety issue of rAAV-mediated microdystrophin gene transfer using larger animal models, such as dystrophic dog models, we first investigated transduction efficiency of rAAV in wild-type canine muscle cells, and found that rAAV2 encoding beta-galactosidase effectively transduces canine primary myotubes in vitro. Subsequent rAAV2 transfer into skeletal muscles of normal dogs, however, resulted in low and transient expression of beta-galactosidase together with intense cellular infiltrations in vivo, where cellular and humoral immune responses were remarkably activated. In contrast, rAAV2 expressing no transgene elicited no cellular infiltrations. Co-administration of immunosuppressants, cyclosporine and mycophenolate mofetil could partially improve rAAV2 transduction. Collectively, these results suggest that immune responses against the transgene product caused cellular infiltration and eliminated transduced myofibers in dogs. Furthermore, in vitro interferon-gamma release assay showed that canine splenocytes respond to immunogens or mitogens more susceptibly than murine ones. Our results emphasize the importance to scrutinize the immune responses to AAV vectors in larger animal models before applying rAAV-mediated gene therapy to DMD patients.
Yuasa
K
K
Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
Yoshimura
M
M
Urasawa
N
N
Ohshima
S
S
Howell
J M
JM
Nakamura
A
A
Hijikata
T
T
Miyagoe-Suzuki
Y
Y
Takeda
S
S
D000818:Animals; D001483:Base Sequence; D002147:Calmodulin / Q000235:genetics; D016572:Cyclosporine / Q000008:administration & dosage; D000229:Dependovirus / Q000235:genetics*; D004285:Dogs; D016189:Dystrophin / Q000235:genetics / Q000378:metabolism; D005818:Genetic Engineering; D015316:Genetic Therapy / Q000009:adverse effects* / Q000379:methods; D005822:Genetic Vectors / Q000009:adverse effects* / Q000235:genetics; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007273:Injections, Intramuscular; D007371:Interferon-gamma / Q000276:immunology; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D023421:Models, Animal; D008969:Molecular Sequence Data; D018485:Muscle Fibers, Skeletal / Q000276:immunology / Q000821:virology; D018482:Muscle, Skeletal / Q000276:immunology*; D009137:Muscular Dystrophy, Animal / Q000276:immunology / Q000628:therapy*; D020388:Muscular Dystrophy, Duchenne / Q000276:immunology / Q000628:therapy*; D010322:Parvoviridae Infections / Q000276:immunology; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013045:Species Specificity; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014161:Transduction, Genetic / Q000379:methods; D019076:Transgenes; D001616:beta-Galactosidase / Q000235:genetics
D002147:Calmodulin; D016189:Dystrophin; D007166:Immunosuppressive Agents; D012333:RNA, Messenger; D007371:Interferon-gamma; D016572:Cyclosporine; D001616:beta-Galactosidase